ClinicalTrials.gg
RecruitingNCT05709353MPATHYUpdated Nov 7, 2023

MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder

A Phase 2 interventional study of Prolonged exposure therapy and MDMA in PTSD, Alcohol Use Disorder and Alcohol Dependence, sponsored by University of Sydney. Recruiting at 2 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-07.

Sponsored by University of Sydney · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.

Planned enrollment
4th of 38
120 · median 25
Started
2023
with 4 others
Phase 2
28 of 38
10 open now
Primary completion
2026-05
later than 0 of 11 live
Registered
24th of 38
by date

Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 4th largest by planned enrollment, is one of 5 that started in 2023, is one of 28 in phase 2, reaches primary completion later than 0 of the 11 other live ones, and was the 24th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About N-Methyl-3,4-methylenedioxyamphetamine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

To explore the effectiveness of of MDMA-assisted prolonged exposure therapy in improving treatment outcomes for individuals with comorbid PTSD and alcohol use disorder in a double-blind randomised placebo-controlled trial.

Read the detailed description

New strategies for the treatment of comorbid PTSD and alcohol dependence are urgently required. Recent evidence has shown strong support for trauma-focused integrated treatments (namely COPE), however, only 49% demonstrate clinically significant improvements. MDMA may be a promising approach to improve response to COPE for this population. Emerging evidence suggests that MDMA-assisted therapy may be of promise for PTSD, and has demonstrated a good safety profile and potential efficacy in alcohol dependence.

This project will evaluate the clinical efficacy and tolerability of MDMA-assisted COPE relative to a control-assisted COPE. Active control used in this study is niacin. The investigators hypothesise that MDMA treated participants will be have a reduction in PTSD symptom severity as well as heavy drinking.

The trial will utilise a double blind, randomised, controlled design. A sample of 120 individuals will receive 14 weeks of treatment including 12 COPE sessions and 2 dosing sessions with MDMA (80-160mg) or control (niacin 250mg).

03

Conditions studied

  • PTSD
  • Alcohol Use Disorder
  • Alcohol Dependence
  • Post-traumatic Stress Disorder
  • Comorbidities and Coexisting Conditions

Keywords

  • MDMA-assisted therapy
  • Randomised-Controlled Trial
  • Comorbid PTSD and AUD
  • MDMA
  • COPE
  • Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure
  • Psychedelic-Assisted Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Both AUD and current PTSD according to the criteria, for 6 months or longer with at least moderate severity, according to investigator judgement and CAPS-5
  2. Aged ≥18 years old
  3. Adequate cognition and English language skills to give valid consent and complete research interviews assessments
  4. Willing to give written
  5. Received prior treatment for PTSD or AUD (not including study interventions)
  6. Stable housing
  7. Able to identify a significant other (such as a family/friend/partner) who could accompany them from clinic/provide transport and/or be contacted by the study team if required

Exclusion criteria

Exclusion Criteria:

  1. History of, or currently meeting, criteria for:

    • current or lifetime psychotic or bipolar disorders, or
    • major depression with psychotic features Assessed via Structured Clinical Interview for DSM-5 - Research Version (SCID-5-RV). Potential participants will be screened for personality disorders but suitability will then be confirmed by clinical interview given the prevalence of high scores in this comorbid population
  2. Pregnant or lactating ( must be used and a sensitive pregnancy test will be performed at baseline and prior to dosing)
  3. Significant alcohol withdrawal (current Clinical Institute Withdrawal Assessment for Alcohol [CIWA-Ar] score ≥10, including history of delirium tremens or alcohol withdrawal seizures).
  4. Concurrent use of psychotropic medication (antidepressants and alcohol pharmacotherapy use considered if assessed by physician and titrated down with 5 half-lives + 1 week washout)
  5. Use of, and unable or unwilling to cease, any medications likely to interact with MDMA in the opinion of the physicians and investigators during the trial (low dose opiates are permitted for pain management but not the night before or after MDMA sessions)
  6. Substance use disorder other than tobacco (e.g. benzodiazepines, cannabis)
  7. Abnormal clinical findings including a history of, or current: cardiac disease and/or dysrhythmia, uncontrolled hypertension or severe hypotension, abnormal findings, stroke, liver disease, a history of epilepsy, hyponatraemia, or malignant hyperthermia (controlled hypertension and diabetes type II may be permitted)
  8. Suicide risk according to clinician judgement and responses to Columbia Suicide Severity Rating Scale-Lifetime (C-SSRS-L) and SCID-5-RV.

    • Details surrounding any previous attempts >6 months ago will be gathered whereby attempts related to their trauma/PTSD and/or associated with the use of psychostimulants will contribute to risk assessment and guide trial safety measures if enrolled
  9. Clinically unstable systemic medical (e.g., cancer) or psychiatric disorder or condition that might require hospitalisation that precludes trial participation
  10. Regular use of ecstasy (e.g. at least twice in last 6 months, or >10 times within the last 5 years)
  11. Enrolled in any other interventional clinical trials in the previous two months or over the duration of the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    COPE + MDMA

    4x COPE sessions Dose 1: 2x MDMA capsules (80mg) + 1x niacin-matched placebo capsule Optional supplementary dispense: 1x MDMA capsule (40mg) 4x COPE sessions Dose 2: 2x MDMA capsules (80mg) + 1x niacin-matched placebo capsule Optional supplementary dispense: 1x OR 2x white MDMA capsule (40 or 80mg) 4x COPE sessions

    Behavioral: Prolonged exposure therapy · Drug: MDMA

  • Other
    COPE + Niacin (Control)

    4x COPE sessions Dose 1: 2x MDMA-matched placebo capsules + 1x niacin capsule (250mg) Optional supplementary dispense: 1x MDMA-matched placebo capsule 4x COPE sessions Dose 2: 2x MDMA-matched placebo capsules + 1x niacin capsule (250mg) Optional supplementary dispense: 1x OR 2x MDMA-matched placebo capsule 4x COPE sessions

    Behavioral: Prolonged exposure therapy · Drug: Niacin

Interventions

  • BehavioralProlonged exposure therapy

    COPE represents an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence (see manual DOI: 10.1093/med:psych/9780199334513.001.0001). COPE used in the current study will represent an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence. COPE only begins when the participant in a safe environment and no longer in contact with the traumatic event/exposure. COPE employs imaginal and in vivo exposures to treat PTSD and consists of 12 individual 90-minute sessions (i.e. 19.5 hours) delivered by a clinical psychologist.

    Also known as: COPE (Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure)

  • DrugN-Methyl-3,4-methylenedioxyamphetamineStudies of N-Methyl-3,4-methylenedioxyamphetamineN-Methyl-3,4-methylenedioxyamphetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administration of 80 to 160 mg MDMA across two 'dosing' sessions. Supplemental doses (additional 40mg during first session, additional 40- 80mg during second session) will be dependent on clinician and participant consensus during preparatory period of 'dosing session'. These supplemental amounts will be dispensed 60 to 90 minutes after initial 80 mg dose.

    Also known as: 3,4-Methyl enedioxy methamphetamine

  • DrugNiacin

    Administration of niacin 250mg or niacin-matched placebo during two 'dosing' sessions.

    Also known as: Control, Vitamin B3

06

What researchers measure

Primary outcomes

  1. change in clinician-rated PTSD severity via Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) (CAPS-5) from baseline to visit 16.

    CAPS-5 is a structured diagnostic interview with excellent psychometric properties and diagnostic efficiency and used widely in MDMA-assisted PTSD studies. The CAPS-5 will be administered by independent evaluators blind to treatment condition. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms. CAPS-5 symptom cluster severity scores are calculated by summing the individual item severity scores for symptoms corresponding to a given DSM-5 cluster: Criterion B (items 1-5); Criterion C (items 6-7); Criterion D (items 8-14); and, Criterion E (items 15-20).

    Time frame: 52 weeks

  2. change in self-reported PTSD symptom severity via Post-Traumatic Stress Disorder Checklist for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) (PCL-5) from baseline to visit 16.

    PCL-5 has excellent psychometric characteristics for a secondary indicator of PTSD symptom severity. Items are summed to provide a total severity score (range = 0-80). The PCL-5 can determine a provisional diagnosis in two ways: Summing all 20 items (range 0-80) and using a cut-point score of 31-33 appears to be reasonable based upon current psychometric work.

    Time frame: 52 weeks

Secondary outcomes

  1. Number of Heavy Drinking Days per week (HDDs) (>5 standard drinks/day for men; >4 for women)

    This will be measured by the Timeline Follow Back and corroborated with Phosphatidylethanol (PEth) levels

    Time frame: 52 weeks

  2. Absence of any HDD

    Measured by Timeline Follow Back and corroborated with Phosphatidylethanol (PEth) levels

    Time frame: 52 weeks

Other outcomes

  1. Mean alcohol consumption per drinking day

    Measured by Timeline Follow Back and corroborated with Phosphatidylethanol (PEth) levels

    Time frame: 52 weeks

  2. Change in dependence Severity

    Measured by the Alcohol Dependence Scale. The minimum score is 0 and the maximum score is 47. A higher score indicates more severe dependence.

    Time frame: 52 weeks

  3. Changes in Anxiety

    Measured by cumulative scores on the DASS-21 Anxiety Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates more anxiety.

    Time frame: 52 weeks

  4. Changes in Depression

    Measured by cumulative scores on the DASS-21 Depression Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates greater depression.

    Time frame: 52 weeks

  5. Changes in Stress

    Measured by cumulative scores on the DASS-21 Stress Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates more stress.

    Time frame: 52 weeks

  6. Sleep Disturbances

    As measured by the ISI (Insomnia Severity Index). This Index has a minimum score of 0 and a maximum score of 28. The higher the score indicates more severe insomnia.

    Time frame: 52 weeks

  7. Drinking Diary

    Daily texts will be sent out to participants querying the amount of alcohol they have consumed. Participant responses to this will be recorded. This will be managed through SEMA software.

    Time frame: 16 weeks

  8. Mood states

    Daily texts will be sent out to participants querying their moods. This will be in line with the POMS instrument (Profile of Mood States).

    Time frame: 16 weeks

  9. Mood following dosing session

    The week following each dosing session will involve calls with participants to complete POMS (profile of mood states)

    Time frame: week 5, week 10

  10. Changes in Suicidal Ideation

    Changes in suicidal ideation \& behaviours across the treatment period. This will be measured on the C-SRSS (Columbia Suicide Severity Rating Scale). At baseline this will be measured by the baseline version. At each visit following this, this will be recorded on the since last visit version. Higher scores indicate more severe suicidality.

    Time frame: 52 weeks

  11. Changes in Quality of Life

    To assess whether treatment can change quality of life as measured by the short form Health Survey (SF-36). This survey has 36 items that measure 8 domains of health, including: physical functioning, physical role limitations, bodily pain, general health perceptions, energy/vitality, social functioning, emotional role limitations and mental health. The scores are transformed to range from 0 (worst possible health) to 100 (best possible health).

    Time frame: 16 weeks

  12. Changes PTSD cognitions

    As measured by the PTCI. This is a 33 question inventory measures negative cognitions about the self \& world, as well as self-blame. Higher scores indicate more negative cognitions.

    Time frame: 52 weeks

  13. Changes in use of Health Services

    As measured by the Brief Health Services Use Questionnaire. This questionnaire assesses Health Service Use across the last 3 months. It is a qualitative questionnaire.

    Time frame: 16 weeks

  14. Therapeutic Alliance between therapist

    As measured by the Helping Alliance Questionnaire (HAQ-II). This instrument will be completed by the patient (patient version) and the clinician (clinician version). This outlines how a person may feel or behave in relation to their therapist. Higher scores indicates a better therapeutic alliance.

    Time frame: 16 weeks

  15. COPE Session Rating Scale

    As measured by the session rating scale (SRS). Following each COPE session, both the therapist and participant will complete a brief post-session rating. This scale measures; relationship, goals \& topics, approach or method and overall psychotherapy session. Higher scores on each of these indicate a more positive experience.

    Time frame: 16 weeks

  16. Treatment Satisfaction as measured by the YES (your experience of service).

    This instrument is designed to gather information from consumers about their experiences of care.

    Time frame: 16 weeks

  17. Treatment Satisfaction ss measured by the CSQ-8 (client satisfaction questionnaire).

    This instrument measures clients satisfaction with treatment. Total scores range from 8 to 32, with the higher number indicating greater satisfaction.

    Time frame: 16 weeks

  18. Measurement of Distress ss measured by a Likert Scale

    This instrument will be administered hourly within the dosing sessions. It aims to measure the participant's mood on a scale of 1 (worst) -10 (best)

    Time frame: week 5, week 12

  19. Measurement of Drug Effect as measured by the Revised Mystical Experience Questionnaire 30 (MEQ-30)

    MEQ-30 Measures mystical, positive mood, transcendence, ineffability experienced in dosing sessions. MEQ-30 will be compelted at the end of each dosing session. participants will be asked to rate rate the degree to which at any time during that session they experienced certain phenomena on a scale of 0 (not at all) to 5 (more than any other time in their life)

    Time frame: week 5, week 12

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for May 2026, 32 months after the start.

Of 87 non-industry phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 59. This study's planned 32 months is below that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2023
First posted
Feb 2, 2023
StartActual
Sep 19, 2023
Primary completionEst.
May 2026
CompletionEst.
May 2026
Last update
Nov 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05709353
Lead sponsor
University of Sydney
Collaborators
Monash University, Sydney Local Health District
Responsible party
Sponsor
First posted
Feb 2, 2023
Start date
Sep 19, 2023
Primary completion
May 2026 (estimated)
Completion
May 2026 (estimated)
Last update
Nov 7, 2023

Study contacts

Kirsten C Morley, PhD
Contact
Kirsten.morley@sydney.edu.au
61295153636
Ellen Towers
Contact
ellen.towers@sydney.edu.au
Kirsten C Morley, PhD
principal investigator · University of Sydney

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion